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Sepsis is an uncontrolled systemic inflammation from an infec­tion. Severe sepsis may result in organ failure and even death. In the early phase of septic shock, proinflammatory cyto­
kines have a crucial role in activating lymphocytes, phagocytes 
and vascular endothelium and in stimulating the release of sec­
ondary mediators to increase vascular permeability, which causes 
tissue damage1,2. The uncontrolled production of proinflammatory 
cytokines can be more damaging than the primary infection3, and 
to prevent septic shock, it is of great importance to terminate the 
excess production of proinflammatory cytokines.
LPS (also called endotoxin) from the outer membrane of 
Gram­negative bacteria incites life­threatening endotoxic shock4. 
It can rapidly activate mitogen­activated protein kinases (MAPKs, 
including ERK, JNK and p38), IκB kinases (IKKs) and several 
downstream transcription factors to control the expression of 
proinflammatory cytokines5,6. Among these transcription factors, 
NF­κB has a central role. NF­κB comprises two subunits, p65 and 
p50, which are retained in the cytoplasm by the inhibitory IκBs. 
Upon stimulation, IκBs are phosphorylated by IKKs and degraded 
through the ubiquitin­proteasome pathway, leading to the translo­
cation of transcription­competent NF­κB to the nucleus7.
MAPK p38 has been implicated as a critical factor upstream of 
NF­κB8,9. It upregulates the expression of a variety of genes in the 
acute phase of inflammatory responses10. Blocking p38 with spe­
cific inhibitors attenuates the expression of NF­κB target genes. 
However, the nuclear translocation or DNA­binding activity of 
NF­κB does not seem contingent on p38 activity8, which suggests 
that p38’s influence on NF­κB may be indirect. It is reported that, 
upon stimulation by a combination of interleukin­1β (IL­1β) and 
interferon­γ (IFN­γ), p38 phosphorylates acetyltransferase coacti­
vator p300 to enhance its association with and its acetylation of 
p65 to activate NF­κB activity in primary human astrocytes11. Still, 
many unknown factors in the p38­dependent regulation of NF­κB 
await further investigation.
Orphan nuclear receptor Nur77 (also called TR3) belongs to the 
NR4A family of nuclear receptors12. Nur77 expression can be rap­
idly induced by a variety of inflammatory stimuli through NF­κB 
binding to the Nur77 promoter in monocytes and macrophages13. 
The anti­inflammatory property of Nur77 has been demonstrated 
in various cell models. Elevation of Nur77 expression reduced the 
expression of several cytokines and chemokines in macrophages 
in response to LPS or TNF­α stimulation14. Nur77 suppressed 
monocyte adhesion by upregulating IκBα expression in human 
endothelial cells15. Mice deficient in Nur77 showed enhanced ath­
erosclerosis and chronic inflammatory disease owing to impaired 
Toll­like receptor signaling as well as macrophages polarized 
toward an inflammatory phenotype16,17. Yet the applicability of 
Nur77 as a molecular target in inflammatory diseases is still to 
be substantiated.
This study reports a mechanism in which NF­κB activity is 
downregulated through a direct Nur77 interaction with p65 to 
block its binding to the κB element. This Nur77 inhibition, how­
ever, is abruptly countered by p38α phosphorylation. Interference 
with the associated p38α­Nur77 interaction would favor Nur77’s 
attenuation of the LPS­induced hyperinflammatory response. 
To this end, a chemical compound, n-pentyl 2­[3,5­dihydroxy 
­2­(1­nonanoyl)­phenyl]acetate (PDNPA), which targets the 
ligand­binding domain (LBD) of Nur77, was identified from an 
in­house, Nur77­biased library. By impeding the interaction 
between Nur77 and p38α, PDNPA abolishes the p38α phosphory­
lation of Nur77 so that Nur77 can effectively inhibit NF­κB activity 
and, as a result, dampen LPS­induced inflammation.
RESULTS
Nur77 knockout makes mice more susceptible to sepsis
To define the role of Nur77 in sepsis, we used LPS to induce the 
initial phase of sepsis in wild­type (WT) mice and Nur77 knockout 
(KO) mice. Although both displayed the symptoms of  endotoxic 
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Sepsis, a hyperinflammatory response that can result in multiple organ dysfunctions, is a leading cause of mortality from 
infection. Here, we show that orphan nuclear receptor Nur77 (also known as TR3) can enhance resistance to lipopolysaccharide 
(LPS)-induced sepsis in mice by inhibiting NF-kB activity and suppressing aberrant cytokine production. Nur77 directly associ-
ates with p65 to block its binding to the kB element. However, this function of Nur77 is countered by the LPS-activated p38a 
phosphorylation of Nur77. Dampening the interaction between Nur77 and p38a would favor Nur77 suppression of the hyper-
inflammatory response. A compound, n-pentyl 2-[3,5-dihydroxy-2-(1-nonanoyl) phenyl]acetate, screened from a Nur77-biased 
library, blocked the Nur77-p38a interaction by targeting the ligand-binding domain of Nur77 and restored the suppression of 
the hyperinflammatory response through Nur77 inhibition of NF-kB. This study associates the nuclear receptor with immune 
homeostasis and implicates a new therapeutic strategy to treat hyperinflammatory responses by targeting a p38a substrate to 
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shock under LPS treatment, such as crouching, shivering and 
disheveled fur, the mortality rate of KO mice was evidently increased 
(Fig. 1a). The body temperature of KO mice also dropped faster in 
the first 24 h of the LPS injection (Fig. 1a). These results suggest 
that Nur77­deficient mice are more susceptible to LPS challenge.
To assess Nur77’s role in organ failure in sepsis, the blood urea 
nitrogen (BUN) level and renal histology were monitored for kid­
ney function. The BUN level increased modestly in WT mice but 
was approximately three times above the background level in KO 
mice after LPS injection (Supplementary Results, Supplementary 
Fig. 1a). Accumulation of red blood cells and tubule dilation were 
also more evident in the kidneys of KO mice after LPS adminis­
tration (Supplementary Fig. 1b). These results indicate renal dys­
function in Nur77­deficient mice upon LPS challenge.
LPS­induced endotoxic shock is accompanied by increased pro­
duction of proinflammatory cytokines. After LPS administration, 
serum concentrations of TNF­α and IL­6 in KO mice were initially 
approximately two­ to threefold higher than those in WT mice but 
then dropped to comparable levels in 8 h. The IL­1β concentration 
in KO mice was elevated to a much higher level than in WT mice 
for a duration of 8 h. The nitric oxide (NO) content, an important 
inflammatory mediator, was also obviously higher in KO than in 
WT mice in the first 6 h of LPS injection (Fig. 1b). These results 
indicate that Nur77­deficient mice are more susceptible to endo­
toxic shock, probably owing to the presence of excess cytokines and 
inflammatory mediators.
The cecal ligation and puncture (CLP) mouse model was also 
used for the investigation. CLP induces a polymicrobial sepsis 
that mimics the later phase of human sepsis18. All KO mice died 
within 3 d after CLP, whereas over 20% of WT mice survived 
by day 7 (Supplementary Fig. 1c). In contrast to WT mice, KO 
mice had much higher levels of bacteria in both spleen and blood 
(Supplementary Fig. 1d,e) as well as more severe kidney injury 
(Supplementary Fig. 1f,g), indicating that they lost the capacity 
to clear blood­borne bacteria. The levels of proinflammatory cyto­
kines, including TNF­α, IL­6 and IL­1β, were also two­ to threefold 
higher in KO mice than in WT mice after CLP (Supplementary 
Fig. 1h). These data suggest that the major role for Nur77 is also 
to limit the production of proinflammatory cytokines in the later 
phase of sepsis.
Nur77 blocks p65 binding to DNA
Peritoneal macrophages were isolated from WT and KO mice 
(Nr4a1+/+ and Nr4a1−/− macrophages, henceforth referred to as 
Nur77+/+ and Nur77−/− macrophages, respectively) for the investi­
gation. After LPS stimulation, the concentrations of TNF­α, IL­6, 
IL­1β and NO were much higher in the culture medium of Nur77−/− 
than Nur77+/+ macrophages (Supplementary Fig. 2a), another 
indication that Nur77 downregulates the production of proin­
flammatory cytokines. To evaluate Nur77’s influence on the LPS­
induced pathways on a global scale, microarrays were used to assay 
gene expression in LPS­stimulated Nur77+/+ and Nur77−/− macro­
phages. Most of the LPS­inducible genes19 were expressed at much 
higher levels in Nur77−/− macrophages (Supplementary Fig. 2b). In 
addition, Nur77−/− macrophages expressed more NF­κB–dependent 
genes20 than did Nur77+/+ macrophages upon LPS stimulation 
(Supplementary Fig. 2c and Supplementary Table 1). Gene set 
enrichment analysis (GSEA) also implied that LPS­downregulated19,21 
or NF­κB–inhibited20,22 gene signatures were markedly enriched, 
whereas LPS­ or NF­κB–upregulated gene signatures were nega­
tively enriched in Nur77+/+ macrophages (Supplementary Fig. 2d). 
These results lend support to the notion that Nur77 is a negative 
regulator in the LPS­stimulated inflammatory response and is nega­
tively correlated with the NF­κB downstream targets.
IκB is a negative regulator of NF­κB23. Although overexpression 
of Nur77 increased IκB­α expression, which suppressed NF­κB 
activation in endothelial cells15, there is no difference in IκB­α 
expression between Nur77+/+ and Nur77−/− macrophages with or 
without the LPS induction (Supplementary Fig. 2e). Moreover, 
p65 had comparable levels of expression and nuclear transloca­
tion in both Nur77+/+ and Nur77−/− macrophages before and after 
LPS treatment (Supplementary Fig. 2e). It is possible that Nur77 
directly influences the transcription activity of NF­κB in mac­
rophages. Indeed, transfection of p65 greatly activated NF­κB 
reporter activity in 293T cells, which could be significantly inhib­
ited by Nur77 (Fig. 2a). LPS­induced NF­κB reporter activity in 
RAW264.7 macrophages was further enhanced by transfecting 
Nur77­targeted siRNA (Fig. 2a), indicating that Nur77 attenuates 
LPS­induced NF­κB activity.
Nur77’s influence on p65 binding to DNA was investigated 
by an electrophoretic mobility shift assay (EMSA) with a specific 
NF­κB probe. In Nur77+/+ macrophages, DNA interaction with p65 
was observed after LPS induction, which was gradually weakened 
afterwards. In contrast, p65 binding to DNA was increased with 
the addition of LPS in Nur77−/− macrophages for as long as 8 h 
(Fig. 2b). This Nur77 modulation of NF­κB DNA binding activ­
ity was also demonstrated by an in vitro assay, in which p65 bind­
ing to its response element was suppressed by recombinant Nur77 
(Supplementary Fig. 2f). This suppression might originate from 
a direct contact, as Nur77 and p65 showed interaction in both co­
immunoprecipitation (co­IP) and glutathione S­transferase (GST) 
pulldown assays (Supplementary Fig. 2g) involving both the trans­
activation domain (TAD) of Nur77 and the LBD (Supplementary 
Fig. 2h,i). The interaction between the LBD and p65 was reported 
previously24. However, transfection of the TAD alone, but not the 
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Figure 1 | Nur77-deficient mice are with elevated sensitivity to  
LPS-induced sepsis. (a) nur77-deficient mice are more vulnerable to 
lpS-induced death. Wt and Ko mice were intraperitoneally injected with 
lpS (10 mg per kg body weight; n = 15). Survival rates (left) and body 
temperatures (right) were recorded. (b) Release of serum inflammatory 
mediators in Wt and Ko mice. After lpS injection, sera from mice (n = 6)  
were collected at the indicated times for analysis of tnF-α, il-6 and 
il-1β by eliSA and of no by bioassay. Kaplan-Meier plots were made, 
and statistical significance was analyzed by a log-rank test. differences 
between the two groups are assessed by two-way AnovA using SpSS 
software. Representatives of three independent experiments with similar 
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(Fig. 2c) and the LPS­induced expression of TNF­α mRNA 
(Supplementary Fig. 2j). Thus, Nur77 suppresses LPS­induced 
NF­κB activity by blocking p65 binding to DNA to attenuate the 
production of proinflammatory cytokines.
p38a phosphorylation hampers Nur77 
inhibition of NF-kB
LPS activates a series of kinases, including 
MAPKs and IKKs, that target transcription 
factors to regulate the expressions of a large 
array of proinflammatory genes5. Nur77 is a 
phosphorylatable transcription factor, and the 
phosphorylation level of its threonine but not 
serine residues was evidently elevated upon 
LPS stimulation in RAW264.7 cells (Fig. 3a). 
In the same cell lysates, the activities of ERK, 
p38, JNK and IKK were all elevated by LPS 
(Supplementary Fig. 3a). However, only 
SB202190, an inhibitor to p38, inhibited the 
LPS­induced phosphorylation of Nur77 at 
threonine residues (Fig. 3b), suggesting that 
p38 is responsible for the LPS­induced phos­
phorylation of Nur77. The role of p38 in phos­
phorylating Nur77 was investigated by two 
additional approaches. First, cotransfection 
of p38α into 293T cells increased threonine 
phosphorylation in Nur77 (Supplementary 
Fig. 3b). Second, in macrophages isolated 
from LtrLysCre­p38αΔ/Δ mice, no phos­
phorylation of Nur77 was observed after LPS 
treatment. In contrast, LPS did induce threo­
nine phosphorylation in Nur77 in p38αfl/fl 
macrophages with normal p38α expression 
(Fig. 3c). These results indicate that p38α 
selectively participates in LPS­induced phos­
phorylation of Nur77.
We also investigated the connection 
between p38α­induced phosphorylation of 
Nur77 and LPS­stimulated NF­κB activity. 
GST­Nur77 effectively blocked p65 binding to 
DNA, which was nullified by phosphorylated 
Nur77 from preincubation with a His­p38α 
(Fig. 3d). Furthermore, transfection of p38α, but not mutant 
p38α­AF, which had no kinase activity, reduced the interaction 
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Figure 2 | Nur77 inhibits NF-kB activation via impairing p65 binding to DNA. (a) nur77 suppresses nF-κb transactivation activity. the nF-κb reporter 
gene, together with p65 and nur77, was transfected into 293t cells (left). RAW264.7 cells were transfected with siRnA to nur77 for 24 h, followed by 
lpS treatment for 9 h (right). the reporter activity was determined by luciferase (luc) assays. HA, hemagglutinin. (b) detection of p65 binding to dnA 
by eMSA using an nF-κb probe. Nur77+/+ and Nur77−/− macrophages were treated with lpS for the times indicated. Anti-p65 antibody was preincubated 
with nuclear extracts to identify p65 (upshifted band). the same probe to nF-κb without biotin labeling was used as a competitor (comp). Mutant 
probe to nF-κb (Mut) was used as a negative control. (c) deletion of the tAd fails to suppress nF-κb activity. plasmids were transfected into 293t cells 
as indicated, and the luciferase assay was performed. images of full blots are shown in Supplementary Figure 8. Representatives of three independent 
































































































Figure 3 | Phosphorylation by p38a abolishes Nur77 function. (a) lpS induces phosphorylation 
in nur77. RAW264.7 cells were treated with lpS (1 h). phosphorylated nur77 was 
immunoprecipitated (ip) with anti-phosphothreonine or anti-phosphoserine antibodies and 
analyzed with an anti-nur77 antibody. tpA (100 ng ml−1, 1 h) was used as a positive control. 
(b) effect of kinase inhibitors on lpS-induced phosphorylation of nur77. RAW264.7 cells were 
pretreated with different inhibitors (10 μM, 15 min) followed by lpS. phosphorylated nur77 was 
detected. Sb, Sb202190 for p38 inhibition; pd, pd98059 for eRK inhibition; Ji, JnK inhibitor ii;  
Sc, Sc-514 for iKK inhibition. (c) effect of p38α on nur77 phosphorylation. Macrophages separated 
from ltrlyscre-p38αΔ/Δ or p38fl/fl mice were treated with lpS. phosphorylated nur77 was detected. 
(d) p38α phosphorylation abolishes the nur77 inhibition on p65 binding to dnA. GSt-nur77 was 
preincubated with His-p38α and subjected to eMSA. Mut, mutant probe; comp, competitor.  
(e) p38α phosphorylates nur77 at thr27 and thr143. bacterially expressed GSt-p38α was 
incubated with His-nur77 or its mutants, and phosphorylated nur77 was detected. ib, immunoblot. 
(f) effect of nur77 or its point mutants on nF-κb activity. plasmids were transfected into 293t cells 
as indicated, and a luciferase assay was performed. images of full blots are shown in Supplementary 
Figure 8. Results are presented as the mean ± s.e.m. Representatives of three independent 
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imply that  phosphorylation by p38α interferes with the interaction 
of Nur77 with p65, thereby abolishing Nur77’s inhibition of p65 
binding to DNA.
Co­IP showed that Nur77 interacted with p38α both endog­
enously and exogenously (Supplementary Fig. 3d). Deleting 153 
residues from the N terminus (Nur77ΔN153) completely abol­
ished p38α phosphorylation of Nur77 (Supplementary Fig. 3e), 
suggesting that the phosphorylated residues are in the TAD. The 
p38 phosphorylation motif, PXS/TP, was associated with residues 
Thr27 and Thr143 in the TAD. Two single point mutants (T27A 
and T143A) and a double point mutant (T27A T143A, referred to 
as the 2A mutant) were generated (Supplementary Table 2). p38α 
phos phorylation could still be detected in either the T27A or T143A 
mutants but not in the 2A mutant (Fig. 3e and Supplementary Fig. 3f), 
suggesting that both Thr27 and Thr143 are substrate sites for p38α.
Unexpectedly, 2A better inhibited NF­κB activity than either 
Nur77 (Fig. 3f) or a mutant that mimicked the phosphorylated 
Nur77 with both Thr27 and Thr143 mutated to glutamic acid 
(referred to as 2E). Transfection of 2A upon LPS stimulation 
in RAW264.7 cells resulted in lower TNF­α mRNA levels com­
pared to that resulting from transfection of either Nur77 or 2E 
(Supplementary Fig. 3g). Taken together, it is a new phenomenon 
that p38α phosphorylation attenuates Nur77 inhibition of NF­κB 
activity, leading to a failure in the regulation of genes downstream 
of NF­κB.
PDNPA impedes the interaction between Nur77 and p38a
The above data indicate that p38α interacts with and subsequently 
phosphorylates Nur77. The LBD was shown to be the domain 
responsible for the direct interaction with p38α (Supplementary 
Fig. 4a). Disrupting this interaction may result in hypophosphoryla­
tion of Nur77 to suppress the LPS­induced inflammatory response. 
To this end, an in­house chemical library biased to the LBD was 
screened on the basis of NF­κB reporter activity in RAW264.7 
cells. A compound, PDNPA (Fig. 4a), which has a high affinity 
to the LBD but not to p38α (Supplementary Fig. 4b), was iden­
tified as an inhibitor to LPS­stimulated NF­κB activity (Fig. 4b). 
The half­maximum inhibitory concentration (IC50) of PDNPA 
on NF­κB activity is about 1.6 μM (Supplementary Fig. 4c). 
This value may not be consistent with its Kd value for Nur77, which 
might be due to the fact that PDNPA does not directly inhibit 
NF­κB activity. Instead, it interferes with the interaction between 
Nur77 and p38 to indirectly inhibit NF­κB activity. In addition, the 
half­maximal concentration of PDNPA inhibition on cell viability 
is 31.5 μM (Supplementary Fig. 4d), which indicates that PDNPA’s 
anti­inflammatory role is independent of the induction of cell 
death. This PDNPA­associated suppression of NF­κB activity was 
Nur77 dependent. Once endogenous Nur77 was knocked down in 
RAW264.7 cells, PDNPA lost its capacity to suppress LPS­induced 
NF­κB reporter activity (Fig. 4b). However, PDNPA did not show 
any influence on Nur77 expression (Supplementary Fig. 4e) and 
stability (Supplementary Fig. 4f). PDNPA suppressed p65 bind­
ing to DNA in Nur77+/+ but not Nur77−/− macrophages (Fig. 4c). 
Moreover, PDNPA evidently suppressed the expression of cyto­
kines downstream of NF­κB, including TNF­α, IL­1β and IL­6, 
in Nur77+/+ macrophages after LPS treatment but in neither LPS­
stimulated Nur77−/− macrophages nor RAW264.7 cells with Nur77 
knocked down (Fig. 4d and Supplementary Fig. 4g). Therefore, 
PDNPA inhibits p65 binding to DNA and NF­κB activation, prob­
ably by interfering with the cross­talk between Nur77 and p38α.
We excluded direct PDNPA attenuation of p38α kinase activity 
as the compound did not influence the elevation of p38α phos­
phorylation at Thr180 and Tyr182, an indicator for p38 activity, 
upon LPS stimulation (Supplementary Fig. 4h). Moreover, MK2, 
a substrate of p38α, was phosphorylated to a similar level before 
and after PDNPA treatment (Supplementary Fig. 4i). These 
results indicate that PDNPA does not modulate p38α kinase activ­
ity. Nevertheless, PDNPA did influence the stability of the p38α–
Nur77 complex. Preincubation of PDNPA reduced the association 
between Nur77 and p38α with an accompanying decrease in 
Nur77 phosphorylation (Fig. 4e). In contrast, PDNPA did not per­
turb the Nur77­p65 interaction (Supplementary Fig. 4j). PDNPA 
also disrupted the endogenous interaction between Nur77 and 
p38α, but not that between Nur77 and p65, under LPS stimulation 
in RAW264.7 cells (Fig. 4f). As a consequence, the LPS­induced 
phosphorylation of threonine in Nur77 was evidently suppressed 
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Figure 4 | PDNPA suppresses NF-kB activation by disrupting the 
interaction between p38a and Nur77. (a) the structure of pdnpA.  
(b) pdnpA inhibits lpS-induced nF-κb activity. left, RAW264.7 cells  
were treated with lpS (100 ng ml−1) and pdnpA (1 μM and 10 μM) for 9 h.  
Right, RAW264.7 cells were transfected with siRnA to nur77 followed by 
lpS with or without pdnpA treatment (10 μM, 9 h). luciferase assays were 
performed. ctrl, control; nS, no significance. (c) pdnpA suppresses lpS-
induced p65 binding to dnA. peritoneal macrophages from Wt or nur77 
Ko mice were treated with lpS and pdnpA (1 h). nuclear extracts were 
prepared for eMSA. comp, competitor; Mut, mutant probe.  
(d) pdnpA suppresses the production of lpS-induced proinflammatory 
cytokine tnF-α. peritoneal macrophages (left) or RAW264.7 cells 
transfected with siRnA (right) were treated with lpS and pdnpA (4 h).  
the culture medium was collected for analysis. (e) pdnpA blocks  
nur77-p38α interaction and nur77 phosphorylation. Recombinant nur77 
was incubated with His-p38α and either pdnpA (1 μM) or dMSo.  
GSt pulldown (left) or the in vitro kinase assay (right) was carried out.  
ib, immunoblot. (f) pdnpA attenuates nur77-p38α interaction in 
RAW264.7 cells. RAW264.7 cells were treated with lpS and pdnpA. 
cell lysates were immunoprecipitated (ip) with anti-nur77 antibody 
and analyzed by western blotting. images of full blots are shown 
in Supplementary Figure 8. Representatives of three independent 
experiments with similar results are shown. Results are presented as the 
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data support the notion that PDNPA impedes 
the interaction between Nur77 and p38α but 
not between Nur77 and p65 to maintain the 
hypophosphorylation of Nur77. In conjunction 
with interfering with the interaction between 
Nur77 and p38α, PDNPA suppressed the LPS­
induced production of proinflammatory cyto­
kines in macrophages from p38αfl/fl mice but not 
LtrLysCre­p38αΔ/Δ mice (Supplementary Fig. 4l).
To analyze the selectivity of PDNPA, we 
separately knocked down expression of all 
three NR4A family members, Nur77 (NR4A1), 
Nurr1 (NR4A2) and NOR­1 (NR4A3), with 
siRNA. Only Nur77 knockdown effectively 
abolished PDNPA inhibition of NF­κB activ­
ity (Supplementary Fig. 4m) and p65 binding 
to DNA (Supplementary Fig. 4n). Although 
PDNPA still bound the LBDs of Nurr1 and 
NOR­1 (Supplementary Fig. 4o), no inter­
action between p38α and either Nurr1 or NOR­1 
could be detected (Supplementary Fig. 4p). 
That PDNPA only binds nuclear receptors in the 
NR4A family, but not other nuclear receptors 
such as AR, ERα and RXRα (Supplementary 
Fig. 4q), is an indication that PDNPA 
selectively induces the anti­inflammatory 
functionality of Nur77 by interfering with the 
interaction between Nur77 and p38α.
PDNPA competes with p38a for LBD 
binding
The complex between LBD and PDNPA was 
made by soaking the crystalline protein with 
the compound. There are two unique LBD 
molecules (molecule I and molecule II) in the 
complex structure, each with a distinct confor­
mation25. PDNPA binds molecule I with a more 
open conformation compared to its binding 
to molecule II (Fig. 5a and Supplementary 
Fig. 5a). No electron density was associated 
with PDNPA at the same location in molecule II, 
which is too narrow to accommodate the com­
pound (Supplementary Fig. 5b). The binding 
site for PDNPA locates among helices H4, H5, 
H11 and H12 (Fig. 5b), which is distinct from 
the canonical ligand­binding site for the clas­
sical nuclear receptors.
Different mutations were made to per­
turb the PDNPA­LBD interaction. The single 
mutations L437W, S441W or D594E partially 
impaired PDNPA binding, whereas triple 
mutation of all three residues (referred to as 
LSD mut; Supplementary Table 2) completely 
abolished the interaction (Supplementary Fig. 5c). The crys­
tal structures of the S441W and L437W D594E mutants showed 
that the introduction of bulkier residues excludes PDNPA binding 
(Fig. 5c). In contrast, additional single mutations at either H516W 
or P597W showed little interference in PDNPA binding to LBD 
(Supplementary Fig. 5d). Docking experiments suggest that the 
N terminus of p38α and PDNPA could bind at the same location 
in the LBD (Fig. 5c,d). Although the triple mutation perturbed the 
interaction with the compound, it did not interfere with the inter­
action between p38α and LBD (Fig. 5d). However, either H516W 
or P597W impaired the LBD interaction with p38α (Fig. 5d). GST 
pulldown assays further verified that mutation of either His516 or 
Pro597 impeded the p38α­LBD interaction, and LSD mutation 
did hamper, albeit not completely, this interaction (Fig. 5e and 
Supplementary Fig. 5e). It was also evident that PDNPA effectively 
obstructed the p38α association with LBD (Fig. 5f). Together, these 
data suggest that PDNPA competes with p38α binding to LBD to 
prevent the p38α phosphorylation of Nur77.
The crevice where PDNPA binds is also the binding site for 
a previously reported antidiabetic compound, ethyl 2­[2,3,4 
trimethoxy­6(1­octanoyl)phenyl]acetate (TMPA)25. Although 
TMPA has a completely distinct function from PDNPA, in which 
it antagonizes Nur77’s interaction with LKB1, there is only a 
subtle difference in binding modes between the two compounds 
(Supplementary Fig. 5f). This raises the question of whether 
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Figure 5 | critical residues for PDNPA binding and p38a interaction. (a) pdnpA (purple) can 
be modeled only in molecule i but not the same location in molecule ii, which has a different 
conformation. (b) pdnpA bound among H4, H5, H11 and H12 and interacted with residues l437, 
S441 and d594. Residues l444, l570 and l596 also provided the more hydrophobic environment 
for the ester alkyl chain and the acyl group in the compound. (c) Residues l437, S441 and d594 
are at the bottom of pdnpA binding site. Mutation of S441 (bottom left) or double mutation 
of l437 and d594 prevents pdnpA from binding owing to space constraints (bottom right). 
(d,e) critical residues in lbd for p38α binding. (d) Molecular docking shows the preferential 
p38α interaction with lbd at the same site with pdnpA binding (top left). Mutation of three 
residues (S441W, l437W and d594e) did not impair p38α binding (top right), whereas H516W 
and p597W did (bottom). ib, immunoblot. (e) A GSt pulldown assay shows that p597 and 
H516 in the nur77 lbd is important for p38 interaction. His-lbd and its different mutants were 
incubated with GSt-p38α or GSt in vitro and analyzed by western blotting. (f) pdnpA impairs the 
nur77 lbd-p38α association. His-lbd was incubated with GSt-p38α in the presence of either 
dMSo or pdnpA (1 μM) and analyzed by western blotting. images of full blots are shown in 
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experiments was carried out to address this issue. First, although 
the mutation of either His516 or Pro597 impaired p38α bind­
ing (Fig. 5d), these mutations did not prevent LKB1 binding 
(Supplementary Fig. 5g). Structural hindrance from three bulky 
mutations in Ser441, Leu437 and Asp594 blocked PDNPA but 
not TMPA binding (Supplementary Fig. 5f). As expected, the 
T595E mutation, which affected LKB1 binding25, did not inter­
fere with p38α binding (Supplementary Fig. 5g). Second, TMPA 
increased the phosphorylation of AMPK in hepatic L02 cells, 
whereas PDNPA did not. Conversely, PDNPA suppressed LPS­
induced TNF­α expression in macrophages, but TMPA did not 
(Supplementary Fig. 5h). Third, PDNPA weakened the  interaction 
between p38α and LBD. In comparison, TMPA dampened the 
interaction between LKB1 and LBD, whereas PDNPA failed to do 
so (Supplementary Fig. 5i). Fourth, LBD mutations C566R and 
T595E impaired both TMPA and LKB1 binding25 but neither p38α 
nor PDNPA binding (Supplementary Fig. 5j). In contrast, muta­
tion of either H516W or P597W suppressed the p38α­LBD asso­
ciation but not the LKB1­LBD interaction. Furthermore, the triple 
mutant (LSD mut) lost the ability to bind PDNPA but not TMPA 
(Supplementary Fig. 5k). Finally, TMPA could not rescue mice 
from the lethal LPS challenge as PDNPA did, yet PDNPA was not 
capable of lowering the blood glucose in diabetic mice like TMPA 
(Supplementary Fig. 5l). It can be concluded that although both 
TMPA and PDNPA bind at the same location, the subtle differ­
ence in their binding is sufficient to induce completely different 
biological outcomes.
PDNPA effectively alleviates two models of sepsis
The physiological potential of PDNPA for treating sepsis was inves­
tigated by using mouse models mimicking the aforementioned two 
separate phases of sepsis. PDNPA treatment was sufficient to cause 
a decrease in the IL­6 concentration (Supplementary Fig. 6a) and 
significantly prolonged the lifespan of WT mice under LPS stimu­
lation (Fig. 6a). WT mice with PDNPA treatment also had a higher 
body temperature within 12 h (Fig. 6a). However, neither survival 
rate nor body temperature in KO mice was affected by PDNPA, 
which corroborated the notion that Nur77 is required for PDNPA’s 
attenuation of sepsis.
TNF­α and IL­6 in the sera of PDNPA­treated WT mice were 
significantly lower than those from the DMSO­treated controls in 
the first ~3–5 h after LPS injection. Concentrations of serum IL­1β 
and NO in PDNPA­treated mice arose more slowly and reached a 
lower peak compared to those of controls (Fig. 6b). This indicates 
that PDNPA administration suppresses the release of cytokines to 
attenuate LPS­induced endotoxic shock. Thus, PDNPA enhances 
mouse resistance to lethal sensitization from the LPS challenge.
PDNPA administration in CLP­induced sepsis increased the 
survival rate of WT mice but not KO mice (Supplementary 
Fig. 6b). As expected, PDNPA­treated WT mice, but not KO mice, 
had reduced bacteria levels and cytokine production (Supplementary 
Fig. 6c,d). Furthermore, LtrLysCre­p38αΔ/Δ mice were more resis­
tant than p38αfl/fl mice to the lethality of LPS­induced sepsis26, and 
PDNPA could rescue mice from lethality with the p38αfl/fl but not the 
LtrLysCre­p38αΔ/Δ genotype (Supplementary Fig. 6e). These results 
are consistent with the notion that LtrLysCre­p38αΔ/Δ mice had atten­
uated cytokine production compared to p38αfl/fl mice, and PDNPA 
reduced cytokine production in p38αfl/fl mice but not in LtrLysCre­
p38αΔ/Δ mice (Supplementary Fig. 6f). Clearly, PDNPA attenuates 
both LPS­ and CLP­induced sepsis via Nur77­p38α cross­talk.
DiScUSSioN
The inflammatory response is a double­edged sword. An appro­
priate inflammatory response helps to remove pathogens, whereas 
an aggressive one leads to multiorgan dysfunction or even death. 
Therefore, understanding the precise regulatory mechanism in 
inflammatory response is critical to solve many inflammation­
 related diseases. In this study, Nur77 is shown to be a vital brake in 
the NF­κB–mediated inflammatory response. Knockout of Nur77 
greatly sensitizes mice to LPS­ and CLP­induced lethality. Nur77 
could suppress NF­κB activity by blocking p65 binding to its κB 
element to attenuate the production of proinflammatory cytokines. 
This Nur77 function, however, is abolished by p38α phosphoryla­
tion upon LPS stimulation. PDNPA, a compound that binds the 
LBD, was identified to impede p38α phosphorylation of Nur77 by 
disrupting the Nur77­p38α interaction. This revealed that Nur77 
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Figure 6 | PDNPA treatment for LPS- and cLP- induced sepsis.  
(a) pdnpA improved the survival rate of mice in lpS-induced sepsis.  
Wt and Ko mice were administered with pdnpA (50 mg per kg body 
weight, intravenous injection) for 2 h, followed by lpS (10 mg per kg  
body weight, intraperitoneal injection; n = 15). Survival rates (left) and  
body temperatures (right) were recorded at the times indicated.  
(b) pdnpA blocks the release of inflammatory mediators in the sera of 
Wt mice. Mice were administrated with lpS and pdnpA as described 
above (n = 6). Sera were collected for the analysis of tnF-α, il-6, il-1β and 
no. (c) An illustration on the regulatory role of nur77 in nF-κb activity, 
p38α phosphorylation of nur77 and pdnpA disruption of nur77-p38α 
interaction in the lpS-induced inflammatory response. Kaplan-Meier  
plots were constructed, and statistical significance was analyzed by a  
log-rank test. Results are presented as the mean ± s.e.m. Representatives  
of two or three independent experiments with similar results are shown.  
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pathway and identified an efficient compound to attenuate the 
inflammatory response (Fig. 6c).
As a check in the NF­κB pathway, Nur77 functions comparably or 
even complementarily in many aspects to IκB. IκB masks p65 in the 
cytosol to prevent NF­κB–associated transcription in the nucleus27. 
Nur77 locates in the nucleus of macrophages but also directly binds 
p65 to prevent its association with the κB element for transcription. 
IκB is ubiquitinated for degradation upon phos phorylation by IKKs, 
which activates NF­κB. p38α phosphorylation dampens the Nur77 
interaction with p65 to relieve the suppression of NF­κB activity. 
Both IκB and Nur77 are involved in the auto regulation of NF­κB. 
IκBα entry to the nucleus leads to the inactivation of DNA­bound 
NF­κB for export to the cytoplasm28,29. Elevated expression of Nur77 
results in the suppression of NF­κB activity. Moreover, Nur77 was 
reported to increase IκBα expression in vascular endothelial cells 
(human umbilical vein endothelial cells)15, which, however, seems 
to be cell line and stimuli dependent.
p38α phosphorylates many transcription factors that control the 
expression of proinflammatory cytokines30,31. This study demon­
strates a new p38α regulatory mechanism, in which phosphoryla­
tion of Nur77 modulates the NF­κB activity and the production of 
proinflammatory cytokines. We demonstrated that phosphoryla­
tion is an important regulatory mechanism for Nur77 functions32,33. 
In macrophages, p38α phosphorylates Nur77 at residues Thr27 and 
Thr143 upon LPS stimulation to diminish Nur77 suppression of 
NF­κB activity, and these are the same residues that are also phos­
phorylated by GSK3β in intestinal tumorigenesis for attenuating 
Nur77’s inhibition on Wnt activity34. Thus, the phosphorylation of 
Nur77 at the same site by different kinases upon different types of 
stimulation can result in different biological outcomes.
There is no physiological ligand for Nur77 identified to date. 
Regulatory compounds targeting Nur77, however, do exist. 
We demonstrated that Csn­B agonized the transactivation 
activity of Nur77 by binding the LBD35. A Csn­B derivative, 
1­(3,4,5­trihydroxyphenyl) nonan­1­one (THPN), interacted with 
the LBD to provide a suitable surface for Nur77’s interaction with 
Nix, leading to Nur77 translocation to the mitochondria to induce 
autophagic cell death in melanoma36. Another Csn­B derivative, 
TMPA, also binds the LBD to block the interaction between Nur77 
and LKB1, facilitating LKB1 shuttling to the cytoplasm to activate 
AMPK activity and decrease the glucose level in diabetic mice25. 
In the current study, neither TMPA nor THPN influences the 
NF­κB transcription activity in RAW264.7 cells or mouse survival 
in the sepsis models. Csn­B slightly inhibits the NF­κB transcrip­
tion activity in RAW264.7 cells but showed no obvious effect on 
LPS­induced mouse sepsis (Supplementary Fig. 7). Conversely, 
PDNPA is an effective anti­inflammatory compound that disrupted 
the interaction between Nur77 and p38 to block the p38­activated 
NF­κB signaling pathway. These Nur77­targeting compounds 
directly influence the interactions between Nur77 and its interact­
ing partners in a new paradigm that is distinct from physiological 
ligand binding at the canonical ligand­binding pocket in traditional 
nuclear receptors. Though these compounds share similarities in 
chemical structure, they have diverse yet specific and nonoverlap­
ping functions. Their discovery paves the way for designing new 
therapeutics to treat various diseases.
PDNPA is a competitive inhibitor to the Nur77­p38 interaction 
rather than an antagonist in the traditional sense as it does not bind 
the canonical pocket. PDNPA is not Nur77 specific as it also binds 
both Nurr1 and NOR­1. However, PDNPA’s functional readout on 
the p38 pathway is Nur77 specific, as only the knockdown of Nur77 
abolished the activity of PDNPA. The binding of PDNPA to either 
Nurr1 or NOR­1 has no phenotypic consequence as neither of them 
interact with p38. In light of the fact that PDNPA does not bind other 
nuclear receptors such as AR, ERα or RXRα, PDNPA is highly spe­
cific for Nur77­associated regulation of the p38α–NF­κB pathway.
Steroidal compounds (such as glucocorticoids) and nonsteroidal 
compounds (such as coxibs) are widely used to treat inflammation. 
However, their safety issues concerning gastrointestinal or car­
diovascular applications cannot be ignored37,38. Developing more 
effective and less toxic agents to treat acute and chronic inflamma­
tory diseases is still a challenge39. As it has a critical role in regulat­
ing the production of proinflammatory cytokines, p38 is a highly 
valued therapeutic target for treating inflammatory diseases. The 
general approach is to develop inhibitors targeting its ATPase 
activity; by 2007, about 20 of these had progressed to clinical tri­
als. To date, however, only SCIO469 and VX702 remain in phase II 
trials40–42 owing to unacceptable safety profiles43–45. Impeding the 
specific interaction between p38 and its substrates is an alterna­
tive approach to reduce the clinical attrition of p38 inhibitors. 
For example, the aniline analog CMPD1 was identified to bind 
p38α and selectively inhibit p38α activity toward the substrate 
MK2 (ref. 46). Nur77 is a new substrate for p38α, and PDNPA is 
a potential anti­ inflammatory compound, competing with p38α 
for Nur77 binding. This specific PDNPA property thus provides 
a unique framework for developing anti­inflammatory drugs with 
few side effects. 
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Accession codes. Protein Data Bank (PDB): The coordinates and 
the structure factors were deposited under accession codes 4RZG 
for PDNPA­bound NUR77 LBD at 2.7­Å resolution, 4RZE for 
NUR77 LBDL437W D594E at 2.49­Å resolution and 4RZF for NUR77 
LBDS441W at 1.99­Å resolution.
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Cell culture, transfection and drugs. Human embryonic kidney (HEK293T) 
cells and mouse monocyte/macrophage RAW264.7 cells were purchased from 
the Institute of Cell Biology, China. Human liver cell line (L02) was purchased 
from Cell Bank in Chinese Academy of Sciences in Kunming. Cell lines were 
cultured in Dulbecco’s Modified Eagle’s Medium (for 293T and RAW 264.7 
cell lines) or RPMI­1640 medium (for L02 cell line) supplemented with 10% 
FBS (FBS; Hyclone, Logan, UT), 100 U penicillin and 100 μg/ml streptomycin. 
Transfection was carried out by using FuGENE HD transfection reagent 
(Promega, Madison, WI) according to the manufacturer’s instructions. 
Lipopolysaccharide (LPS, E. coli 0111:B4, Sigma) was dissolved in PBS.
PDNPA was dissolved in DMSO. Different doses of PDNPA were used to test 
NF­κB transcription activity, and 10 μM PDNPA was determined to be suitable 
for the study. The concentration of TMPA was determined as reported25.
Plasmids construction. pGL6­NF­κB­Luc reporter with four NF­κB response 
elements (GGGAATTTCC) inserted into the pGL6­TA vector was purchased 
from the Beyotime Institute of Biotechnology (cat. no. D2207). Human p38α 
constructs with either a Flag or GST tag were generous gifts from J. Han at 
Xiamen University. Human p65, Nur77, Nurr1, NOR­1 and their deletions 
were constructed with either pCMV5­HA or pET­22b vectors.
Experimental animal models. Wild­type and Nur77­KO mice (C57BL/6J 
background) were purchased from the Jackson Laboratory. LtrLysCre­p38αΔ/Δ 
and p38αfl/fl mice were provided by J. Han (Xiamen University, China)26. Mice 
were maintained in 12­h light/12­h dark cycles with free access to food and 
water. PDNPA and TMPA were dissolved in DMSO to a final concentration 
of 1 M and diluted with 5.0% (v/v) Tween­80 and 0.9%(w/v) saline. DMSO 
in 5.0% (v/v) Tween­80 and 0.9% (w/v) saline was used as the vehicle control. 
All procedures were performed in compliance with the guidelines from the 
Institutional Animal Care and Use Committee at Experimental Animal Centre 
in Xiamen University (acceptance no. XMULAC20120030).
Mouse model for LPS-induced sepsis. Eight­week­old WT and KO mice were 
intraperitoneally injected with 10 mg per kg body weight LPS. After injection, 
body temperatures and survival rates were recorded. Serum and tissue samples 
were collected as required. To test efficacy, mice were intravenously injected 
with either PDNPA (50 mg per kg body weight) or TMPA (50 mg per kg body 
weight) 2 h before LPS injection (10 mg per kg body weight).
Mouse model for CLP-induced sepsis. Eight­week­old mice were weighed and 
anesthetized. Lower quadrants of the abdomen were shaved, and a skin midline 
incision was made. The cecum of each mouse was ligated in the middle and 
perforated by a single through­and­through puncture midway between the 
ligation and the tip of the cecum with a 21G needle. After removing the needle, 
the cecum was extruded with a small amount of feces and then relocated. The 
peritoneum of mice was then closed and resuscitated by injecting prewarmed 
saline (37 °C, 1 ml per mouse) subcutaneously. The mice were placed back in 
cages and monitored every 6 h after the operation. Sham mice underwent a 
similar procedure as CLP mice, including anesthetizing and abdominal mid­
line incision, with the exception that the cecum in shams was not manipulated. 
For PDNPA administration, PDNPA (50 mg per kg body weight) was intrave­
nously injected after the operation.
HFD/STZ-induced mice with type II diabetes. To induce diabetes, WT 
C57BL/6J mice (8­week­old) were fed a high­fat diet (HFD; Research Diets) 
containing 60% kcal from fat. After 4 weeks of dietary manipulation, mice were 
treated with a low dose of STZ (Sigma; 35 mg per kg body weight dissolved in 
0.1 M sodium citrate buffer, pH 4.5) once daily for 7 d. To evaluate whether 
type II diabetes was established in the mice, blood glucose was monitored, 
and frank hyperglycemia was observed in HFD­induced mice but not in nor­
mal diet–fed mice after STZ treatment. The diabetic mice were treated with 
TMPA (50 mg per kg body weight) or PDNPA (50 mg per kg body weight) by 
intraperitoneal injection once daily for 19 days, and the blood glucose of the 
mice was analyzed at the times indicated in Supplementary Figure 5l after 
fasting for 12 h.
Isolation and culture of peritoneal macrophages. Three days before isolation, 
mice were intraperitoneally injected with 2 ml 4% thioglycollate medium (BD). 
Peritoneal macrophages were collected by peritoneal lavage with 10 ml cold 
PBS. Cells were incubated in DMEM supplemented with 10% FBS at 37 °C for 
2 h and washed with PBS to eliminate nonadherent cells. The adherent cells 
were used as peritoneal macrophages.
Assay for inflammatory indicators and cytokines. Blood urea nitrogen (BUN) 
and nitric oxide (NO) levels were determined using commercially available kits 
(Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the 
manufacturer’s instructions. The concentrations of TNF­α, IL­6 and IL­1β 
were determined using ELISA kits (eBioscience, San Diego, CA) according to 
the manufacturer’s instructions.
The kinase assay in vitro. Purified GST­Nur77 or its mutants were incubated 
with pure His­p38α in a 50­μl reaction mixture containing 25 mM Tris­HCl 
(pH 7.4), 10 mM magnesium chloride, 5 mM β­glycerol phosphate, 1 mM 
dithiothreitol (DTT), 0.1 mM sodium orthovanadate and 50 μM ATP. The 
mixture was incubated at 30 °C for 30 min. The reaction was terminated with 
the loading buffer for SDS­PAGE.
Nuclear extracts and EMSA. Cells were lysed in 100 μl Buffer A (10 mM 
HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.15% NP­40) 
and 1% protease inhibitor for 15 min and centrifuged at 12,000g for 30 min at 
4 °C. The pellet was washed three times with 1 ml Buffer A, resuspended in 
150 μl Buffer B (20 mM HEPES, pH 7.9, 0.4 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 0.5% NP­40) containing 1% protease inhibitor and sonicated. The 
supernatant was used as the nuclear fraction.
To analyze the relationship between p38α phosphorylation of Nur77 and 
p65 binding of DNA, bacterially expressed Nur77 was phosphorylated by 
Ni­bound p38α as described in the kinase assay, with removal of p38α by 
precipitation. The supernatant was used as phosphorylated Nur77 in EMSA. 
Nur77 incubated with Ni­NTA beads was used as the control.
The κB element and its mutant were labeled with biotin at both ends, and 
EMSA was carried out according to the manufacturer’s protocols (Pierce). 
The gel shift was detected by using a LightShift Chemiluminescent EMSA Kit 
(Thermo) according to the manufacturer’s instructions.




Co-IP and western blotting analysis. Cells were lysed in modified ELB 
(150 mM NaCl, 100 mM NaF, 50 mM Tris­HCl, pH 7.6, 0.5% Nonidet P­40 
(NP­40) and 1 mM PMSF) or lysis buffer (50 mM HEPES, pH 7.4,100 mM 
NaCl,10% glycerol,1% Triton X­100, 1.5 mM MgCl2, 25 mM NaF and 1 mM 
PMSF). Cell lysates were incubated with the appropriate antibody together 
with protein A–Sepharose beads for 3 h. The protein­antibody complexes 
on the beads were subjected to western blotting analysis. Mouse anti­HA 
(cat. no. H­9658, 1:5,000 for western blotting), anti­Flag (cat. no. F­1804, 
1:5,000 for western blotting) and anti­β­tubulin (cat. no. T4026, 1:5,000 for 
western blotting) antibodies were purchased from Sigma. Rabbit anti­Myc 
(cat. no. SC­789, 1:1,000 for western blotting), mouse anti­GFP 
(cat. no. SC­9996, 1:1,000 for western blotting), rabbit anti­p65 (cat. no. SC­372, 
1:1,000 for western blotting) and rabbit anti­IκBα (cat. no. SC­371, 
1:1,000 for western blotting) antibodies were purchased from Santa Cruz 
Biotechnology. Rabbit anti­phosphothreonine (cat. no. 9381S, 1:1,000 for 
western blotting), anti­p38 (cat. no. 9212S, 1:1,000 for western blotting), anti­ 
phospho­p38 T180/Y182 (cat. no. 4511S, 1:1,000 for western blotting), anti­Nur77 
(cat. no. 3960S, 1:1,000 for western blotting), anti­phospho­JNK 
(cat. no. 9255S, 1:1,000 for western blotting) and anti­phospho­IKKα/β  
(cat. no. 2697P, 1:1,000 for western blotting) antibodies were purchased from 
Cell Signaling Technology. Rabbit anti­phosphoserine antibody (cat. no. 618100, 
1:2,000 for western blotting) was purchased from Invitrogen.
Luciferase reporter assay. Cells were transfected with the pGL6­NFκB­Luc 
reporter constructs, β­galactosidase (β­gal) expression vectors and other rele­
vant plasmids. Twenty­four hours after transfection, the luciferase activity was 
measured and normalized for transfection efficiency to internal β­gal activity.
The GST pulldown assay in vitro. GST or GST­fusion proteins were expressed 
in E. coli strain BL21 and purified using glutathione­Sepharose (Sigma). His­
fusion proteins were expressed in E. coli strain BL21 and purified using Ni­NTA 
agarose (Qiagen). The bead­bound GST or GST­fusion proteins were incu­
bated with 500 ng His­tagged protein in 400 μl modified ELB buffer (150 mM 
NaCl, 100 mM NaF, 50 mM Tris­HCl, pH 7.6, 0.5% Nonidet P­40 (NP­40) and 
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modified ELB buffer three times. The proteins were eluted by boiling in load­
ing buffer for 10 min for SDS­PAGE.
Real-time PCR. Total RNA was extracted using the RNeasy kit (Qiagen) and 
reverse transcribed with M­MuLV reverse transcriptase (Fermentas). cDNA 
was amplified using primers specific for Tnf­α and Actin mRNA. Real­time 
PCR was performed using Sybr Green–based detection in the Rotor­Gene 
according to the manufacturer’s instruction. Actin mRNA levels were used as 
the controls for normalization. The primers were as below (5′­3′):
Tnf-α: forward, AGCCCACGTCGTAGCAAACCA; reverse, CGGGGC 
AGCCTTGTCCCTTG
Actin: forward, CAGCCTTCCTTCCTGGGCATG; reverse, ATTGTG 
CTGGGTGCCAGGGCAG
16s rRNA; forward, GTGGTGCATGGTTGTCGTCA; reverse, ACGTCG 
TCCCCACCTTCCTC
Microarrays and GSEA. Peritoneal macrophages (Nur77+/+ and Nur77−/−) were 
isolated from WT and Nur77 KO mice, respectively (n = 3). After LPS treatment 
(100 ng/ml, 1 h), cells were harvested for RNA extraction using TRIzol reagent 
(Invitrogen). The microarrays were carried out by China National Engineering 
Center for Biochip at Shanghai. Heat maps were generated through the SBS 
Analysis System (http://sas.ebioservice.com/).
Gene expression data from Nur77+/+ and Nur77−/− macrophages (three WT 
mice versus three KO mice) were used as inputs for the GSEA analysis. The 
GSEA software v2.0.14 (http://www.broadinstitute.org/gsea/)47 was used for 
the GSEA analysis. Gene sets were either obtained from the MSigDB database 
v4.0 or from published gene signatures. Statistical significance was assessed by 
comparing the enrichment score to enrichment results generated from 1,000 
random permutations of the gene set to obtain P values (nominal P value).
Crystallization, data collection and processing. Crystals of apo LBD of Nur77 
and its mutants were obtained at 16 °C by hanging­drop vapor diffusion. 
The droplets consisted of a 1:1 (v/v) mixture of LBD at 6 mg/ml and the well 
solution of 100 mM sodium citrate, pH4.2, 20% glycerol and 7.5% PEG4000. 
Crystals appeared after 36–48 h and were ready for data collection in 14 d. For 
the formation of the complexes, crystals were soaked in a reservoir solution 
containing an additional 0.5 mM PDNPA before being transferred to a cryo­
solution comprising the reservoir solution and 5% (v/v) glycerol, 1.5% (v/v) 
PEG4000 and 0.75 mM PDNPA and then were incubated for 3 h. The crys­
tals were flash­cooled in liquid nitrogen to −170 °C. The diffraction data were 
collected at 100 K under the synchrotron radiation at beamline BL17U1 of the 
Shanghai Synchrotron Radiation Facility (SSRF). The data sets were integrated 
and scaled with the HKL2000 package.
The structures of LBD, its mutants and its complexes with PDNPA were 
determined by molecular replacement with the structure of LBD (PDB acces­
sion code 3V3E) as the initial search model with the program Phaser48. The 
programs Refmac5 and Coot9 (ref. 49) in the CCP4 suite50–52 were used for 
the refinement and model building. Ramachandran plots were generated with 
Coot9. The statistics for data processing and structure refinement are shown 
in Supplementary Table 2.
Fluorescence quenching assay. Fluorescence spectra were obtained as previ­
ously described25. Briefly, His­fusion proteins were expressed in E. coli strain 
BL21, purified and dialyzed against PBS (pH 7.4). For analyzing the interac­
tions between the protein and compounds, 5 μM proteins were incubated with 
various concentrations of compounds, and fluorescence quenching was moni­
tored at 25 °C with a slit width of 5 nm for excitation and a slit width of 2.5 nm 
for emission. The excitation wavelength was 280 nm, and the emission spectra 
were recorded from 285 nm to 410 nm. To estimate the binding affinity, the 
fluorescence intensities at 334 nm with increasing concentrations of quencher 
were measured, and the values of Kd were calculated according to the law of 
mass action formula53.
Modeling the interaction between Nur77 and p38a. Coordinates for the LBD 
(PDB code 3V3E) and p38α (PDB code 1M7Q) were obtained from the PDB 
for docking with the program ZDOCK54 implemented in Discovery Studio 
3.1 (Accelrys Software Inc., San Diego), which modeled and simulated the 
interactions between two molecules. LBD was the receptor, and p38α was the 
ligand. The docking poses were clustered on the basis of the all­atom r.m.s. 
deviation of any two ligands. Poses from each cluster with high ZDock Scores 
were selected and minimized by RDOCK55 using the CHARMm force field56. 
One complex structure with p38α located in LBD of Nur77 was identified in 
the top ten binding poses ranked by E_RDock value. The complex was further 
optimized using molecular dynamics simulations by the Desmond program, 
version 3.1 (Schrödinger, New York) using the OPLS2005 force field57,58, which 
performed high­speed molecular dynamics simulations of biological systems 
on conventional commodity clusters. The LBD and p38α complex were sol­
vated in TIP3P water molecules using an orthorhombic box that can fit the 
molecule with a 12­Å buffer zone. The system was neutralized by the addition 
of Na+ ions. The systems were relaxed before simulation by using the default 
Desmond protocol. A 2­ns simulation was carried out using the NPT ensemble 
with a target pressure of 1.0132 bar and a temperature of 300 K.
Statistical analysis. Survival curves were analyzed by Kaplan­Meier using a 
log­rank test. Data are expressed as mean ± s.e.m. The differences between two 
groups were assessed by a two­tailed unpaired Student’s t­test or by one­way or 
two­way ANOVA with SPSS software (version 13; SPSS Inc., Chicago, IL).
Synthesis of PDNPA. Synthetic PDNPA was fully characterized by 1H NMR, 
13C NMR, MS and elemental analysis. A summary of the synthetic procedure 
of PDNPA is as follows35:
PDNPA is a white solid with melting point 97–98 °C; IR (film): 3,334 cm−1, 
2,956 cm−1, 2,927 cm−1, 2,856 cm−1, 1,708 cm−1, 1,614 cm−1, 1,591 cm−1, 1,466 cm−1, 
1,416 cm−1, 1,377 cm−1, 1,329 cm−1, 1,260 cm−1, 1,162 cm−1, 1,112 cm−1, 1,046 cm−1, 
1,017 cm−1; 1H NMR (400 MHz, CDCl3) δ 0.88 (t, J = 6.9 Hz, 3H, ­CH3), 
0.90 (t, J = 7.0 Hz, 3H, ­CH3), 1.18–1.37 (m, 14H, 7 × CH2), 1.59–1.74 
(m, 4H, 2 × CH2), 2.83 (t, J = 7.4 Hz,2H,­CH2CO), 3.83 (s, 2H, ­CH2CO), 
4.13 (t, J = 6.8 Hz, 2H, ­CH2­), 6.26 (d, J = 2.4 Hz, 1H, ArH), 6.27 (d, J = 2.4 Hz, 
1H, ArH), 6.46 (brs, 1H, ­OH), 12.04 (brs, 1H, ­OH); 13C NMR (100 MHz, 
CDCl3) δ 13.9, 14.1, 22.3, 22.6, 25.0, 28.0, 28.2, 29.1, 29.3, 29.4, 31.8, 41.7, 43.4, 
65.9, 103.2, 112.7, 116.5, 136.6, 160.3, 164.3, 171.7, 206.7; MS (ESI) m/z 402 
(M+Na+, 100%); Analysis calculated for C22H34O5: C, 69.81; H, 9.05. Found: 
C, 69.65; H, 8.81.
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